Immunotherapy using PD-1/PD-L1 inhibitors has played a central role in the treatment of not only non–small-cell lung cancer (NSCLC) but also many other types of cancer, bringing about a breakthrough in cancer treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.